The HIRN gratefully acknowledges support provided by a grant from The Leona M. and Harry B. Helmsley Charitable Trust for the HIRN Annual Investigator Meetings.
Samples and Reagents
The HIRN investigators are partnering with multiple programs to obtain samples and reagents for their studies, including resources obtained from:
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) funded IIDP coordinates the distribution of high quality human islets to the diabetes research community, in order to advance scientific discoveries and translational medicine. The IIDP works closely with 6 Islet Isolation Centers to support investigators requiring human islets, including access to normal and T2D human islets and accompanying histology and donor data to support their studies.
The Network for Pancreatic Organ donors with Diabetes (nPOD) is a JDRF-supported research program that strives to maintain a network of procuring and characterizing, in a collaborative manner, pancreata and related tissues (spleen, lymph nodes, pancreatic lymph nodes, peripheral blood, thymus, bone marrow, skin) from cadaveric organ donors with type 1 diabetes as well as those whom are islet autoantibody positive. These tissues are also obtained from persons without type 1 diabetes (age 0 to 75), type 2 diabetes, and other diseases where pancreatic involvement is likely. Utilizing these high quality (i.e., transplant grade) tissues, investigators will work together to address key immunological, histological, viral, and metabolic questions and generate a comprehensive analysis of human type 1 diabetes leading to a cure for the disease.
Type 1 Diabetes TrialNet is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. TrialNet is conducting clinical trials with researchers in the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand. Studies are available for people newly diagnosed with type 1 diabetes, as well as for relatives of people with type 1 diabetes who are at greater risk of developing the disease.
The NIDDK has funded a Type 1 Diabetes Resource (T1DR) at The Jackson Laboratory (TJL). The purpose of this resource is to collect and cryopreserve ~150 mouse stocks important to research in type 1 diabetes.This major NIDDK-directed collaborative effort currently has an increased emphasis on preclinical research model development. Expanded T1DR activities are focused on development/refinement of mouse models expressing HLA or other molecules associated with disease susceptibility in patients, and on the use of these stocks to support engraftment with human immune cells or other tissues.